Clinical Information

Effect of next generation pulsatile mechanical circulatory support on cardiac mechanics – The PULSE trial

We are pleased to announce our newest publication in the Cardiovascular Revascularization Medicine from the desk of Prof. Nicolas van Mieghem and Dr. Marcelo Bastos. MCS is increasingly used in the context of high-risk percutaneous coronary intervention (PCI). The effect of the pulsatile iVAC 2L MCS on left ventricular loading conditions and myocardial oxygen consumption (MVO2) is unknown. In this publication, the Erasmus University Medical Centre & Kings College London showcase their clinical experiences with the iVAC 2L device and outline the impact on patients with advanced coronary artery disease at high to prohibitive operative risk in their practice. Please check this link for the full publication.

Joint EAPCI/ACVC expert consensus document on pVAD

An expert consensus has been released by the Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) reviewing the pathophysiological context and indications for pVADs in different clinical settings. It also provides guidance regarding the clinical management of patients requiring pVADs. A quick overview is made on the state-of-the art of short-term mechanical circulatory support according to different indications. Additional discussions on the handling of complications, anticoagulation and weaning are also provided. The appendix section describes the theoretical basis for the use of different MCS devices, including how their effects differ. The review has been published on EuroIntervention. Please follow this link for the full publication.

PULsecath mechanicaL Support Evaluation (PULSE) – ongoing trial

Prof.Dr. Nicolas van Mieghem, Erasmus Medical Center Brief Summary: The objective of this study is to determine ventricular loading conditions during and after PulseCath®  iVAC 2L support, and assess its impact on specific load dependent humoral factors and cardiac enzymes. These specific patterns are so far unknown and will be compared with the validated FDA-cleared and CE marked Impella CP. Three cases with Impella CP will be performed in this study to obtain the exact same measurements for comparing purposes. لعبة go For more information about this trial, please follow this link.